Jennifer R. Brown

Jennifer Brown leads the CLL Center at Dana-Farber and is one of the world's most prominent CLL researchers. Her research has defined mechanisms of resistance to BTK inhibitors including the BTK C481S mutation and alternative pathway activation, and has guided development of non-covalent BTK inhibitors to overcome resistance. She has participated in pivotal trials of ibrutinib, acalabrutinib, and venetoclax and contributes to national CLL guidelines. Her translational research bridges genomic characterization of CLL biology with clinical outcomes.